CytoDyn (OTCMKTS:CYDY - Get Free Report) posted its earnings results on Friday. The biotechnology company reported ($0.01) EPS for the quarter, Zacks reports.
CytoDyn Trading Up 0.7%
Shares of OTCMKTS CYDY traded up $0.00 during midday trading on Wednesday, reaching $0.28. 725,109 shares of the stock were exchanged, compared to its average volume of 2,863,857. CytoDyn has a 52-week low of $0.10 and a 52-week high of $0.49. The stock has a 50 day moving average price of $0.32 and a 200-day moving average price of $0.27. The company has a market capitalization of $344.17 million, a P/E ratio of 27.53 and a beta of 1.17.
CytoDyn Company Profile
(
Get Free Report)
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Recommended Stories
Before you consider CytoDyn, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytoDyn wasn't on the list.
While CytoDyn currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access